ALUR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Allurion Technologies Inc (ALUR) is not a strong buy at this time for a beginner investor with a long-term focus. While the FDA approval for its Gastric Balloon System is a positive catalyst, the company's poor financial performance, declining revenue, and significant net income losses make it a risky investment. Additionally, there are no strong trading signals or significant insider/hedge fund activity to support a buy decision. The stock is better suited for monitoring rather than immediate investment.
The MACD is positive but contracting, indicating a lack of strong momentum. RSI is neutral at 49.624, and moving averages are converging, suggesting no clear trend. The stock is trading below its pivot point of 1.44, with key support at 1.043 and resistance at 1.837. Overall, technical indicators do not suggest a strong buy signal.
The company received FDA approval for its Gastric Balloon System, opening opportunities in the non-surgical weight-loss market. Additionally, the warrant exercise agreement enhances liquidity for future growth initiatives.
Concerns over discounted warrant exercises have caused a decline in share price. Furthermore, the company's financials show a significant YoY decline in revenue (-50.48%), net income (-236.03%), and EPS (-145.00%), indicating poor financial health.
In Q3 2025, revenue dropped to $2.658 million (-50.48% YoY), net income fell to -$11.884 million (-236.03% YoY), EPS declined to -1.53 (-145.00% YoY), and gross margin decreased to 49.06 (-15.37% YoY). These metrics highlight significant financial struggles.
Chardan analyst Keay Nakae upgraded the stock to Buy from Neutral with a $3 price target, citing FDA approval as a key growth opportunity. However, this is a single analyst's view and does not outweigh the company's financial challenges.
